First in Human Clinical Trial of ApTOLL in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 18, 2019

Primary Completion Date

February 27, 2020

Study Completion Date

March 20, 2020

Conditions
Stroke
Interventions
DRUG

ApTOLL

ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.

OTHER

Placebo

100 mL 0.9% Sodium Chloride solution

Trial Locations (1)

28006

Clinical Pharmacology Department. Hospital Universitario de La Princesa, Madrid

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ministry of Science and Innovation, Spain

OTHER_GOV

collaborator

Anagram

UNKNOWN

lead

aptaTargets S.L.

INDUSTRY

NCT04742062 - First in Human Clinical Trial of ApTOLL in Healthy Volunteers | Biotech Hunter | Biotech Hunter